Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Vutrisiran (Amvuttra)

decorative image of the issue cover

Published April 23, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses vutrisiran (Amvuttra), 25 mg/0.5 mL, prefilled syringe, subcutaneous injection.
  • Indication: Proposed for the treatment of cardiomyopathy in adult patients with wild-type or hereditary transthyretin-mediated amyloidosis.